Search
CELL BANK Website

Back Back
RCB1549 : YSCCC  update : 2018/07/06
CommentHuman cell line derived from cholangiocellular carcinoma. Cell growth is slow.
Comment from the depositor
Restriction (Category)a
Terms and conditionsBasically, there is no restriction regarding academic use.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Imanishi, Hiroyasu
Originator Imanishi, Hiroyasu
Year of deposit 1999
Another name CCC
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 70 years
Tissue liver, ascites meta
Case history cholangiocellular carcinoma
Metastastatic ability Yes
Metastatsd tissue ascites
Classification cancer
Lifespan infinite
Morphology lymphocyte-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Chromosome mode 65-73(50) : /67(5),68(8),69(10),70(11),71(8),72(4)/
Images
deposit info
lot info
Reference information Reference 0
User's Publication 3


To topTop
Reference

To topTop
User's Publication
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941
7938  Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.  Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.  J. Gastroenterol.  2011  46:779-89  PubMed ID: 21331764
10658  Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.  Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.  Oncol. Rep.  2018  39:843-850  PubMed ID: 29251327



Back Back Return Top Page